Together these findings provide strong mechanistic rationale for the clinical use of inhibitors of the c-Met pathway in combination with EGFR TKIs in treatment of lung cancer patients and may have implications in other cancers that demonstrate c-Met-EGFR cross-talk as well. Here, EGFR is linked to lung carcinoma.